Dewpoint is translating new insights into biomolecular condensates and cellular function to uncover treatments for the toughest diseases. Dewpoint is harnessing recent insights into biomolecular condensates elucidated by founders Anthony Hyman of the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden and Richard Young of the Whitehead Institute with the goal to uncover treatments for the toughest diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/30/19 | $60,000,000 | Series A |
6 Dimensions Capital Alexandria Real Estate Equities EcoR1 Capital Leaps by Bayer Polaris Partners  Samsara BioCapital | undisclosed |
| 02/03/22 | $150,000,000 | Series C |
3E Bioventures ARCH Venture Partners EcoR1 Capital Leaps by Bayer Maverick Ventures Mirae Asset Venture Investment Mubadala Capital NS Investment Polaris Partners Samsara BioCapital SoftBank Vision Fund 2 | undisclosed |
